- Letter to the Editor
- Open Access
Tigecycline pharmacokinetics in critically ill patients on renal replacement therapy: possible warnings and potential perspectives for the research agenda
Annals of Intensive Care volume 10, Article number: 141 (2020)
To the editor:
Honore et al.  suggested important insights into papers on tigecycline pharmacokinetics/pharmacodynamics in critically ill patients [2, 3], which warrant further considerations.
Eleven patients (34.4%) included in our trial  underwent continuous renal replacement therapy with low-adsorptive high-flux membranes (acrylonitrile, AN69), which was set in continuous standard volume veno-venous hemodiafiltration (CVVHDF, effluent dose prescribed 35 ml/kg/min) modality and used regional citrate anticoagulation. Although Broeker et al.  did not use regional citrate anticoagulation for CVVHDF and such molecule may theoretically interfere with tigecycline plasma protein binding, thus increasing drug-free fraction and extracorporeal removal, the amount of tigecycline clearance was not clinically relevant (14.8% or even smaller due to filter performance decrease over time vs 13% of the total elimination via renal excretion ) compared to patients with hypoalbuminemia . Such finding is justified by the lipophilic nature of tigecycline (supported by high volume of distribution [2, 3]), which makes the amount of tigecycline removed negligible and disconnected from plasma protein binding and concentration .
However, we support the warning launched by Honore et al.  about the potential of molecules’ removal and consequent need for medication dose adjustments when new membranes are used in daily clinical practice. Furthermore, the greater clearance of antibiotics and small molecules associated with high-volume hemofiltration (effluent dose 70 ml/kg/h), as compared with standard volume hemofiltration reported in the IVOIRE study , is a matter of concern. Accordingly, we would suggest to titrate drug prescription during renal replacement therapy to specific membrane characteristics and effluent dose delivered to match patient’s need in a timely manner (e.g., acid–base imbalance or fluid overload), especially when hydrophilic medications with low plasma protein binding are prescribed and severe hypoproteinemia occurs . Moreover, we advocate the need for further studies on molecules’ removal by renal replacement therapy and other extracorporeal organ supports, to inform clinicians about the impact of new membranes adsorptive properties, at different effluent doses, on drug pharmacokinetics and patients’ related outcome.
Availability of data and materials
Continuous veno-venous hemodiafiltration
Honore PM, David C, Kugener L, Redant S, Attou R, Gallerani A, De Bels D. No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure. Crit Care. 2020;24(59):1–2.
Broeker A, Wicha S, Dorn C, Kratzer A, Schleibinger M, Kees F, Heininger A, Kees M, Häberle H. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. Crit Care. 2018;22(1):341.
De Pascale G, Lisi L, Ciotti GMP, Vallecoccia MS, Cutuli SL, Cascarano L, Gelormini C, Bello G, Montini L, Carelli S, et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care. 2020;10(94):1–9.
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–51.
Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet J-L, Dewitte A, Flamens C, Pujol W, Grandoulier A-S, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39(9):1535–46.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Cutuli, S.L., De Pascale, G., Lisi, L. et al. Tigecycline pharmacokinetics in critically ill patients on renal replacement therapy: possible warnings and potential perspectives for the research agenda. Ann. Intensive Care 10, 141 (2020). https://doi.org/10.1186/s13613-020-00759-4